Antimicrobial susceptibility monitoring of dermatological bacterial pathogens isolated from diseased dogs and cats across Europe (ComPath results).
OBJECTIVE
The ComPath project is a pan-European programme dedicated to the monitoring of antimicrobial susceptibility of pathogens from diseased dogs and cats using standardized methods and centralized minimum inhibitory concentration (MIC) determination. Here, the susceptibility of major pathogens is reported from antimicrobial nontreated animals with acute clinical signs of skin, wound or ear infections in 2008-2010.


RESULTS
MICs were determined by agar dilution for commonly used antibiotics and interpreted using CLSI breakpoints, if available. Of the 1408 strains recovered, the main canine species was Staphylococcus pseudintermedius, followed by Pseudomonas and Streptococcus. In cats, Pasteurella multocida and Staph. pseudintermedius were most prevalent. For Staph. pseudintermedius, resistance was 18·4-25·2% for penicillin, clindamycin and chloramphenicol, but below 11% for ampicillin, amoxi/clav and fluoroquinolones. For Staphylococcus aureus, beta-lactam resistance was high (26·7-62·1%) but low (0·0-4·4%) for other antibiotics. 6·3% of Staph. pseudintermedius and 5·4% of Staph. aureus were confirmed mecA-positive. Gentamicin and fluoroquinolones exhibited moderate activity against Pseudomonas aeruginosa. For streptococci, resistance was absent/very low for penicillin, ampicillin, chloramphenicol and fluoroquinolones. For Escherichia coli, resistance was low to fluoroquinolones, chloramphenicol and gentamicin. No resistance was observed in Past. multocida.


CONCLUSIONS
Overall, antimicrobial resistance was low in skin and soft tissue infections in dogs and cats. The results show the need for ongoing monitoring.


CONCLUSIONS
The results are a reference baseline for future surveillance. The paucity of clinical breakpoints underlines the need to set breakpoints for relevant antibiotics.
CEESA ComPath Study Group, Brussels, Belgium.
C
C
Ludwig
CEESA ComPath Study Group, Brussels, Belgium. anno.jong@bayer.com.
A
A
de Jong
CEESA ComPath Study Group, Brussels, Belgium.
H
H
Moyaert
CEESA ComPath Study Group, Brussels, Belgium.
F
F
El Garch
LGC, Fordham, UK.
R
R
Janes
CEESA ComPath Study Group, Brussels, Belgium.
U
U
Klein
LGC, Fordham, UK.
I
I
Morrissey
CEESA ComPath Study Group, Brussels, Belgium.
J
J
Thiry
CEESA ComPath Study Group, Brussels, Belgium.
M
M
Youala
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001424:Bacterial Infections / Q000382:microbiology / Q000662:veterinary*; D002371:Cat Diseases / Q000382:microbiology*; D002415:Cats; D004283:Dog Diseases / Q000382:microbiology*; D004285:Dogs; D024881:Drug Resistance, Bacterial / Q000235:genetics; D004926:Escherichia coli / Q000187:drug effects; D005060:Europe; D008826:Microbial Sensitivity Tests; D016979:Pasteurella multocida / Q000302:isolation & purification; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D017192:Skin Diseases, Bacterial / Q000382:microbiology / Q000662:veterinary*; D013210:Staphylococcus / Q000187:drug effects / Q000302:isolation & purification; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification
D000900:Anti-Bacterial Agents
antimicrobial susceptibility monitoring; companion animals; minimal inhibitory concentrations; resistance surveillance; skin; wound and ear infection